BioLife Solutions, Inc. (NASDAQ:BLFS) Short Interest Update

BioLife Solutions, Inc. (NASDAQ:BLFS) was the target of a significant growth in short interest in December. As of December 31st, there was short interest totalling 3,310,000 shares, a growth of 5.8% from the December 15th total of 3,130,000 shares. Based on an average daily trading volume, of 379,000 shares, the days-to-cover ratio is presently 8.7 days.

Insider Transactions at BioLife Solutions

In other news, CFO Troy Wichterman sold 987 shares of the business’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $27.02, for a total transaction of $26,668.74. Following the transaction, the chief financial officer now owns 121,779 shares of the company’s stock, valued at approximately $3,290,468.58. The trade was a 0.80 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Greef Roderick De sold 46,896 shares of the business’s stock in a transaction dated Thursday, October 31st. The shares were sold at an average price of $23.43, for a total transaction of $1,098,773.28. Following the transaction, the chief executive officer now directly owns 414,958 shares in the company, valued at approximately $9,722,465.94. The trade was a 10.15 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 103,129 shares of company stock valued at $2,344,018 over the last 90 days. 2.20% of the stock is currently owned by corporate insiders.

Institutional Trading of BioLife Solutions

A number of large investors have recently made changes to their positions in BLFS. Rhumbline Advisers increased its stake in shares of BioLife Solutions by 4.7% during the second quarter. Rhumbline Advisers now owns 87,473 shares of the medical equipment provider’s stock worth $1,875,000 after buying an additional 3,912 shares during the period. Texas Permanent School Fund Corp increased its stake in BioLife Solutions by 8.7% in the second quarter. Texas Permanent School Fund Corp now owns 33,859 shares of the medical equipment provider’s stock valued at $726,000 after purchasing an additional 2,714 shares during the last quarter. Oppenheimer Asset Management Inc. increased its stake in BioLife Solutions by 84.5% in the second quarter. Oppenheimer Asset Management Inc. now owns 33,296 shares of the medical equipment provider’s stock valued at $714,000 after purchasing an additional 15,252 shares during the last quarter. Envestnet Asset Management Inc. increased its stake in BioLife Solutions by 261.5% in the second quarter. Envestnet Asset Management Inc. now owns 127,215 shares of the medical equipment provider’s stock valued at $2,726,000 after purchasing an additional 92,021 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in BioLife Solutions by 9.1% in the second quarter. Dimensional Fund Advisors LP now owns 794,971 shares of the medical equipment provider’s stock valued at $17,034,000 after purchasing an additional 66,422 shares during the last quarter. 93.24% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

BLFS has been the topic of several recent research reports. TD Cowen boosted their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Craig Hallum upped their target price on shares of BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Benchmark reaffirmed a “buy” rating and issued a $30.00 target price on shares of BioLife Solutions in a research report on Thursday, December 19th. Northland Securities upped their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research report on Wednesday, January 8th. Finally, HC Wainwright decreased their target price on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. One analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $29.43.

BioLife Solutions Stock Down 1.2 %

Shares of BLFS opened at $26.14 on Monday. The stock has a market capitalization of $1.21 billion, a PE ratio of -24.66 and a beta of 1.92. BioLife Solutions has a 1 year low of $14.50 and a 1 year high of $28.88. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The company’s 50-day simple moving average is $26.09 and its 200-day simple moving average is $24.58.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.